[1]侯丁丁,赵 力.Ⅱ~Ⅲ期结肠癌术后辅助化疗方案[J].医学信息,2021,34(18):6-9.[doi:10.3969/j.issn.1006-1959.2021.18.002]
　HOU Ding-ding,ZHAO Li.Adjuvant Chemotherapy After Surgery for Stage Ⅱ~Ⅲ Colon Cancer[J].Medical Information,2021,34(18):6-9.[doi:10.3969/j.issn.1006-1959.2021.18.002]
点击复制

Ⅱ~Ⅲ期结肠癌术后辅助化疗方案()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年18期
页码:
6-9
栏目:
出版日期:
2021-09-18

文章信息/Info

Title:
Adjuvant Chemotherapy After Surgery for Stage Ⅱ~Ⅲ Colon Cancer
文章编号:
1006-1959（2021）18-0006-04
作者:
侯丁丁; 赵 力
清华大学第一附属医院普外科，北京 100016
Author(s):
HOU Ding-ding; ZHAO Li
General Surgery,the First Hospital of Tsinghua University,Beijing 100016,China
关键词:
结肠癌; 辅助治疗; 高危因素; 微卫星不稳定性; 循环肿瘤DNA
Keywords:
Colon cancer; Adjuvant therapy; High-risk factors; Microsatellite instability; Circulating tumor DNA
分类号:
R735.3+5
DOI:
10.3969/j.issn.1006-1959.2021.18.002
文献标志码:
A
摘要:
Ⅱ期结肠癌高危因素中以T4对总生存期影响最大，Ⅱ期高危组可推荐3个月XELOX方案或6个月FOLFOX方案。对于Ⅲ期高危组仍Ⅰ类推荐6个月XELOX或者FOLFOX化疗方案，低危组可行3个月XELOX化疗方案。不同分子标志物对结肠癌预后的影响不一，MSI-H是Ⅱ~Ⅲ期结肠癌预后较好指标，RAS或者BRAF突变型的MSS结肠癌预后较差，HER-2阳性者结肠癌能从5-Fu辅助治疗中获益，PIK3CA突变型高危Ⅱ结肠癌和Ⅲ结肠癌应用阿司匹林期尚无明确资料证实，术后循环肿瘤DNA是结肠癌有价值的预后因子，本文从Ⅱ~Ⅲ期结肠癌术后辅助化疗方案和疗程选择进行综述。
Abstract:
Among the high-risk factors of stage Ⅱ colon cancer, T4 has the greatest impact on overall survival. For stage Ⅱ high-risk group, a 3-month XELOX program or a 6-month FOLFOX program can be recommended.For stage Ⅲ high-risk group, 6-month XELOX or FOLFOX chemotherapy is still recommended for category Ⅰ, and 3-month XELOX chemotherapy is recommended for low-risk group.Different molecular markers have different effects on the prognosis of colon cancer. MSI-H is a good prognostic indicator for colon cancer of stage Ⅱ~Ⅲ, and the prognosis of RAS or BRAF mutant MSS colon cancer is poor.HER-2 positive colon cancer can benefit from 5-Fu adjuvant therapy, PIK3CA mutant high-risk colon cancer Ⅱ and Ⅲ colon cancer using aspirin stage has no clear data to confirm that postoperative circulating tumor DNA is a valuable prognosis for colon cancer factor,this article reviews the options of adjuvant chemotherapy and course of treatment after surgery for stage Ⅱ to Ⅲ colon cancer.

参考文献/References:

[1]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.[2]Petrelli F,Ghidini M,Cabiddu M,et al.Microsatellite Instability and Survival in Stage Ⅱ Colorectal Cancer:A Systematic Review and Meta-analysis[J].Anticancer Res,2019,39(12):6431-6441. [3]中国临床肿瘤学会(CSCO)结直肠癌专家委员会,可切除的进展期结直肠癌围手术期治疗专家共识(2019)[J].中华胃肠外科杂志,2019,22(8):701-710.[4]Babcock BD,Aljehani MA,Jabo B,et al.High-Risk Stage Ⅱ Colon Cancer:Not All Risks Are Created Equal[J].Ann Surg Oncol,2018,25(7):1980-1985.[5]Quah HM,Chou JF,Gonen M,et al.Identification of patients with high-risk stage Ⅱ colon cancer for adjuvant therapy[J].Dis Colon Rectum,2008,51(5):503-507.[6]中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)结直肠癌诊疗指南(2020版)[M].北京:人民卫生出版社,2020:144.[7]Petrelli F,Labianca R,Zaniboni A,et al.Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage Ⅱ Colorectal Cancer:A Subgroup Analysis of the TOSCA Randomized Clinical Trial[J].JAMA Oncol,2020,6(4):547-551.[8]Souglakos J,Boukovinas I,Kakolyris S,et al.Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage Ⅱ and stage Ⅲ colon cancer patients:the efficacy results of Hellenic Oncology Research Group(HORG)participation to the International Duration Evaluation of Adjuvant Chemotherapy(IDEA)project[J].Ann Oncol,2019,30(8):1304-1310.[9]Bregni G,Rebuzzi SE,Sobrero A.The Optimal Duration of Adjuvant Therapy for Stage Ⅲ Colon Cancer:the European Perspective[J].Curr Treat Options Oncol,2019,20(1):8.[10]Grothey A,Sobrero AF,Shields AF,et al.Duration of Adjuvant Chemotherapy for Stage Ⅲ Colon Cancer[J].N Engl J Med,2018,378(13):1177-1188.[11]Greally M,Ilson DH.Duration of Adjuvant Chemotherapy in Colon Cancer:Current Standards and New Updates[J].Curr Colorectal Cancer Rep,2019,15(4):122-129.[12]National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology. Colon Cancer, Version 4.2020[EB/OL].[2021-01-01].http://www.nccn.org/.[13]Alwers E,Jansen L,Blaker H,et al.Microsatellite instability and survival after adjuvant chemotherapy among stage Ⅱ and Ⅲcolon cancer patients:results from a population-based study[J].Mol Oncol,2020,14(2):363-372.[14]国家卫生健康委员会中国结直肠癌诊疗规范(2020年版)[J].中华胃肠外科杂志,2020,23(6):521-540.[15]Zaanan A,Shi Q,Taieb J,et al.Role of Deficient DNA Mismatch Repair Status in Patients With Stage Ⅲ Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy A Pooled Analysis From 2 Randomized Clinical Trials[J].JAMA Oncol,2018,4(3):379-383.[16]Taieb J,Zaanan A,Le Malicot K,et al.Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage Ⅲ Colon Cancer Treated With Leucovorin,Fluorouracil,and Oxaliplatin With or Without Cetuximab A Post Hoc Analysis of the PETACC-8 Trial[J].JAMA Oncol,2016,2(5):643-653.[17]Feng Y,Li Y,Huang D,et al.HER2 as a potential biomarker guiding adjuvant chemotherapy instage II colorectal cancer[J].Eur J Surg Oncol,2019,45(2):167-173.[18]Paleari L,Puntoni M,Clavarezza M,et al.PIK3CA Mutation,Aspirin Use after Diagnosis and Survival of Colorectal Cancer.A Systematic Review and Meta-analysis of Epidemiological Studies[J].Clin Oncol(R Coll Radiol),2016,28(5):317-326.[19]Miyamoto K,Takashima A,Mizusawa J,et al.Efficacy of aspirin for stage Ⅲ colorectal cancer:a randomized double-blind placebo-controlled trial(JCOG1503C,EPISODE-Ⅲ trial)[J].Jpn J Clin Oncol,2019,49(10):985-990. [20]Tie J,Cohen JD,Wang Y,et al.Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage Ⅲ Colon Cancer[J].JAMA Oncol,2019,5(12):1710-1717.[21]Bi F,Wang Q,Dong Q,et al.Circulating tumor DNA in colorectal cancer:opportunities and challenges[J].Am J Transl Res,2020,12(3):1044-1055.

相似文献/References:

[1]苏周荣,杜东霖,魏正强.左半结肠癌伴梗阻一期切除吻合策略研究[J].医学信息,2018,31(10):51.[doi:10.3969/j.issn.1006-1959.2018.10.016]
　SU Zhou-rong,DU Dong-lin,WEI Zheng-qiang.Strategy of One-stage Resection and Anastomosis for Left Colon Cancer with Obstruction[J].Medical Information,2018,31(18):51.[doi:10.3969/j.issn.1006-1959.2018.10.016]
[2]崔忠泽,何 双,路丽祯,等.基于生物信息学分析筛选结肠癌关键基因[J].医学信息,2022,35(10):1.[doi:10.3969/j.issn.1006-1959.2022.10.001]
　CUI Zhong-ze,HE Shuang,LU Li-zhen,et al.Screening Key Genes of Colon Cancer Based on Bioinformatics Analysis[J].Medical Information,2022,35(18):1.[doi:10.3969/j.issn.1006-1959.2022.10.001]
[3]石 磊,孙新增,李宝山,等.Ⅱ、Ⅲ期结肠癌患者辅助化疗XELOX方案、FOLFOX方案的临床疗效、不良反应及生活质量对比[J].医学信息,2018,31(13):68.[doi:10.3969/j.issn.1006-1959.2018.13.020]
　SHI Lei,SUN Xin-zeng,LI Bao-shan,et al.Clinical Efficacy,Adverse Reactions and Quality of Life of Adjuvant Chemotherapy XELOX and FOLFOX in Patients with Stage II and III Colon Cancer[J].Medical Information,2018,31(18):68.[doi:10.3969/j.issn.1006-1959.2018.13.020]
[4]王 超,范小华,张 力,等.下腔静脉畸形伴腹腔多脏器异位合并结肠癌1例[J].医学信息,2018,31(18):188.[doi:10.3969/j.issn.1006-1959.2018.18.062]
　WANG Chao,FAN Xiao-hua,ZHANG Li,et al.a Case of Inferior Vena Cava Malformation Associated with Multiple Abdominal Organ Ectopic Colon Cancer[J].Medical Information,2018,31(18):188.[doi:10.3969/j.issn.1006-1959.2018.18.062]
[5]操利超,张核子,余晨笛,等.CLDN11在结肠癌中的预后价值及其作为潜在免疫治疗靶点的研究[J].医学信息,2022,35(14):10.[doi:10.3969/j.issn.1006-1959.2022.14.002]
　CAO Li-chao,ZHANG He-zi,YU Chen-di,et al.The Prognostic Value of CLDN11 in Colon Cancer and its Potential Immunotherapy Targets[J].Medical Information,2022,35(18):10.[doi:10.3969/j.issn.1006-1959.2022.14.002]
[6]黄富全.结合靶向药物综合治疗结肠癌肝及肝外转移术后7年1例报告[J].医学信息,2019,32(01):186.[doi:10.3969/j.issn.1006-1959.2019.01.061]
[7]葛菁茹,朱静雅,苏日新,等.以肺转移为首发表现的结肠癌预后分析[J].医学信息,2021,34(04):96.[doi:10.3969/j.issn.1006-1959.2021.04.025]
　GE Jing-ru,ZHU Jing-ya,SU Ri-xin,et al.Prognostic Analysis of Colon Cancer with Lung Metastasis as the First Manifestation[J].Medical Information,2021,34(18):96.[doi:10.3969/j.issn.1006-1959.2021.04.025]
[8]韩 猛,薛三宝,倪 丰.CT与MRI术前诊断结肠癌及评价术后复发的价值[J].医学信息,2021,34(21):175.[doi:10.3969/j.issn.1006-1959.2021.21.050]
　HAN Meng,XUE San-bao,NI Feng.Value of CT and MRI in Preoperative Diagnosis and Postoperative Recurrence of Colon Cancer[J].Medical Information,2021,34(18):175.[doi:10.3969/j.issn.1006-1959.2021.21.050]
[9]李 丹,陈文直.子宫肉瘤的术前诊断研究[J].医学信息,2020,33(03):34.[doi:10.3969/j.issn.1006-1959.2020.03.011]
　LI Dan,CHEN Wen-zhi.Preoperative Diagnosis of Uterine Sarcoma[J].Medical Information,2020,33(18):34.[doi:10.3969/j.issn.1006-1959.2020.03.011]
[10]操利超,巴 颖,卢晓萍,等.基于TCGA和GEO数据库构建结肠癌预后模型[J].医学信息,2021,34(24):27.[doi:10.3969/j.issn.1006-1959.2021.24.006]
　CAO Li-chao,BA Ying,LU Xiao-ping,et al.Prognostic Model of Colon Cancer Based on TCGA and GEO Database[J].Medical Information,2021,34(18):27.[doi:10.3969/j.issn.1006-1959.2021.24.006]

更新日期/Last Update: 1900-01-01